Unlock instant, AI-driven research and patent intelligence for your innovation.

Inhibitors of nedd8-activating enzyme

A technology of compounds, chemical entities, applied in the field of cell proliferation disorders, active compounds

Inactive Publication Date: 2014-06-25
MILLENNIUM PHARMA INC
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0020] At this time, no inhibitors of E1-activating enzymes have been approved by the government health administration as a treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitors of nedd8-activating enzyme
  • Inhibitors of nedd8-activating enzyme
  • Inhibitors of nedd8-activating enzyme

Examples

Experimental program
Comparison scheme
Effect test

example

[0142] abbreviation

[0143]

[0144]

[0145] one method

[0146] X-ray powder diffraction. XRPD was performed using a Bruker AXS D8 advanced X-ray diffractometer. Approximately 100 mg of sample was gently flattened onto a 50 mm diameter quartz sample disk for powder measurements. Samples were scanned continuously from 2.9 to 29.6° 2Θ using 2Θ / Θ locked coupling angles. Each angular interval is 0.05° 2Θ and data is collected for 2 seconds. Sample runs were performed under ambient conditions and all data were analyzed using EVA version 9.0 software.

[0147] thermal analysis. Thermal events were analyzed using differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). A TA Instruments DSC Q200 and TGA Q500 were used for all sample runs. Thermograms were analyzed using Thermal Advantage for Q-Series software.

[0148] Differential Scanning Calorimetry. Samples (1-2 mg) were sealed in aluminum pans with lids. The sample was heated from 25 °C t...

example 1

[0150] Example 1. Synthesis of (1R,2S)-5-chloro-2-methoxyindan-1-amine (8)

[0151] Step 1: rel-(1aR,6aS)-4-Chloro-6,6a-dihydro-1aH-indeno[1,2-b]oxirane (2).

[0152] To a stirred solution of 4-phenylpropylpyridine-N-oxide (278 mg, 1.31 mmol) in dichloromethane (20 mL) at 0°C was added (R,R)-Jacobson's catalyst (237.0 mg, 0.3732mmol) and sodium hypochlorite solution (2.0M aqueous solution; 16mL, 32mmol). The resulting brown suspension was stirred at 0 °C for 15 minutes, then a solution of 6-chloro-1H-indene (1) (2.81 g, 18.6 mmol) in dichloromethane (20 mL) was added via syringe along with additional sodium hypochlorite (2.0 M in water; 16 mL, 32 mmol). The reaction was stirred at 0 °C for 1 hour, then the ice bath was removed and the reaction was stirred at room temperature for 1 hour. An aliquot was taken and TLC on silica gel (hexanes) showed that all starting material was consumed. The reaction was poured into brine and extracted with dichloromethane. The combined ext...

example 2

[0164] Example 2. Sulfamic acid {(1S, 2S, 4R)-4-[(6-{[(1R, 2S)-5-chloro-2-methoxy-2,3-dihydro-1H-indene- Synthesis of 1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl ester (I-216)

[0165] Step 1: rel-(1R,5R)-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)cyclopent-2-en-1-ol (10).

[0166] To rel-(1R,5R)-5-(hydroxymethyl)cyclopent-2-en-1-ol (47.20g, 0.4135mol), N,N-dimethylamino To a solution of pyridine (2.52 g, 0.0207 mol) and 1H-imidazole (30.97 g, 0.4549 mol) in dichloromethane (800 mL, 10 mol) was added tert-butyldimethylsilyl chloride (28.0 g, 0.186 mol). The reaction was stirred at 0 °C for 2.5 h at which time tert-butyldimethylsilyl chloride (28.0 g, 0.186 mol) was added. The reaction was stirred for another 2 hours. The reaction was quenched by adding saturated aqueous NaCl (200 mL) and water (200 mL). The layers were separated and the organic layer was washed with water (3×200 mL) and brine (1×200 mL), washed with Na 2 SO 4 Dry, filter and concentrate in ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyciopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.

Description

technical field [0001] The present invention relates to compounds, compositions and methods for the treatment of various disorders, particularly cell proliferative disorders, including cancer and inflammatory disorders. In particular, the present invention provides compounds that inhibit the activity of NEDD8-activating enzyme. Background technique [0002] Post-translational modification of proteins by ubiquitin-like molecules (ubls) is an important regulatory process in cells, playing a key role in the control of many biological processes, including cell division, cell signaling, and immune responses. Ubl is a small protein that is covalently linked to a lysine on the target protein via linkage of an isopeptide to the C-terminal glycine of ubl. Ubiquitin-like molecules alter the molecular surface of target proteins and can affect properties such as protein-protein interactions, enzyme activity, target stability and cellular localization. [0003] Ubiquitin and other ubls...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04C07D487/02A61K31/519A61K31/505A61P35/00
CPCC07D239/46C07D473/02C07D239/47C07D473/34A61P35/00
Inventor 阿什利·苏·麦卡伦托德·B·塞尔斯马修·史提灵斯蒂芬·G·斯特劳德
Owner MILLENNIUM PHARMA INC